A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)

Part of paid clinical trials in Gilbert, Arizona.

Sponsor
Rigel Pharmaceuticals
Study ID
NCT02612558
Phase
PHASE2
Status
Completed

Conditions

  • Warm Antibody Autoimmune Hemolytic Anemia

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Fostamatinib 150 mg bid — DRUG
    Fostamatinib 150 mg bid. The dose of Fostamatinib may be reduced at any time to as low as 100 mg PO once daily (qd) if dose limiting adverse events are observed.

Study Details

The purpose of this study is to evaluate whether fostamatinib is safe and effective in the treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA).

Key Dates

Start date
Jul 31, 2016
Status verified
Jul 2021
Primary completion
Dec 31, 2019
Completion
Dec 31, 2019

Study Design

Enrollment
26 participants (actual)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Fostamatinib 150 mg
    Fostamatinib 150 mg bid (morning and evening) over the course of 24 weeks

Primary Outcome Measure

Hemoglobin response [ Time Frame: by Week 24 ]

Locations (31)

FacilityCityStateZIPSite coordinators
Banner MD Anderson Cancer CenterGilbertArizona85234-
Arizona Oncology Associates, PCTucsonArizona85711-
UC San Diego Moores Cancer CenterLa JollaCalifornia92093-
Loma Linda University Cancer CenterLoma LindaCalifornia92350-
LAC/USC Health CenterLos AngelesCalifornia90033-
University of California at San FranciscoSan FranciscoCalifornia94158-
The Oncology Institute of Hope and InnovationWhittierCalifornia90603-
MedStar Georgetown University HospitalWashington D.C.District of Columbia20007-
Mid-Florida Hematology & Oncology Centers, P.A.Orange CityFlorida32763-
Montgomery Cancer CenterMount SterlingKentucky40353-
Johns Hopkins University School Of MedicineBaltimoreMaryland21205-
Rcca Md LlcBethesdaMaryland20817-
Massachusetts General HospitalBostonMassachusetts02114-
MidMichigan Health Cancer CenterMidlandMichigan48640-
University of MinnesotaMinneapolisMinnesota55455-
Robert Wood Johnson University HospitalNew BrunswickNew Jersey08903-
Roswell Park Cancer InstituteBuffaloNew York14263-
Montefiore Medical CenterThe BronxNew York10467-
Brody School of Medicine at East Carolina UniversityGreenvilleNorth Carolina27834-
W.G. "Bill" Hefner VA Medical CenterSalisburyNorth Carolina28144-
Cleveland Clinic FoundationClevelandOhio44195-
The Ohio State University Wexner Medical CenterColumbusOhio43210-
Promedica Flower HospitalSylvaniaOhio43560-
M. Francisco Gonzalez, M.D., P.A.SumterSouth Carolina29150-
Texas Oncology San Antonio Medical CenterSan AntonioTexas78240-
Clear Lake SpecialtiesWebsterTexas77598-
Huntsman Cancer InstituteSalt Lake CityUtah84112-
University of UtahSalt Lake CityUtah84132-
University of WashingtonSeattleWashington98105-
West Virginia UniversityMorgantownWest Virginia26506-
Froedtert HospitalMilwaukeeWisconsin53226-

Find similar trials in Gilbert, AZ

By research site
Banner MD Anderson Cancer Center· Gilbert, AZArizona Oncology Associates, PC· Tucson, AZUC San Diego Moores Cancer Center· La Jolla, CALoma Linda University Cancer Center· Loma Linda, CALAC/USC Health Center· Los Angeles, CAUniversity of California at San Francisco· San Francisco, CA

Related Studies